Research programme: anticancer antibodies - Viventia/Affitech
Latest Information Update: 03 Feb 2011
At a glance
- Originator Affitech AS; Viventia Biotech
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Feb 2008 Preclinical development is ongoing
- 17 Aug 2005 BIO-2005 review
- 03 Feb 2005 Affitech has achieved a research milestone in the discovery and selection of several antibodies